Raltegravir Plus Nucleoside Reverse-Transcriptase Inhibitor (NRTI) Plus Lopinavir, NRTIs Plus Lopinavir for Second-Line Treatment of HIV: 96-Week Follow-up Results from a Randomized Controlled Trial

Huiyi Zhu, Xinmin Duan, Wei Cao, Lianfeng Lu, Xiaojing Song, Ting Zhu, Yang Han, Taisheng Li

PDF(1600 KB)
Journal of Biological Regulators and Homeostatic Agents ›› 2023, Vol. 37 ›› Issue (10) : 5247-5256. DOI: 10.23812/j.biol.regul.homeost.agents.20233710.507
Article

Raltegravir Plus Nucleoside Reverse-Transcriptase Inhibitor (NRTI) Plus Lopinavir, NRTIs Plus Lopinavir for Second-Line Treatment of HIV: 96-Week Follow-up Results from a Randomized Controlled Trial

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

Highlight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2023, 37(10): 5247-5256 https://doi.org/10.23812/j.biol.regul.homeost.agents.20233710.507

References

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
Article Options
  • PDF (45 views)
  • Full Text ( views)

Accesses

Citation

Detail

Sections
Recommended

/